U.S. markets close in 1 hour 46 minutes
  • S&P 500

    4,131.75
    -9.84 (-0.24%)
     
  • Dow 30

    33,797.73
    +120.46 (+0.36%)
     
  • Nasdaq

    13,883.83
    -112.27 (-0.80%)
     
  • Russell 2000

    2,259.95
    +31.03 (+1.39%)
     
  • Crude Oil

    63.14
    +2.96 (+4.92%)
     
  • Gold

    1,734.60
    -13.00 (-0.74%)
     
  • Silver

    25.42
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1980
    +0.0026 (+0.22%)
     
  • 10-Yr Bond

    1.6410
    +0.0180 (+1.11%)
     
  • GBP/USD

    1.3784
    +0.0032 (+0.23%)
     
  • USD/JPY

    108.9500
    -0.0980 (-0.09%)
     
  • BTC-USD

    62,325.29
    -854.46 (-1.35%)
     
  • CMC Crypto 200

    1,340.17
    -35.61 (-2.59%)
     
  • FTSE 100

    6,939.58
    +49.09 (+0.71%)
     
  • Nikkei 225

    29,620.99
    +82.29 (+0.28%)
     

Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

EVANSTON, Ill., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 12, 2019 at 5:00 p.m. EST to report third quarter 2019 financial results and discuss recent business highlights.

To access the live conference call, please dial 1-866-930-5579 (domestic) or 1-409-216-0606 (international) and refer to conference ID 4280058. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Investor & Media Contact:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com
847-871-0377

Source: Aptinyx Inc.